InvestSMART

Epiminder Limited (ASX:EPI)

ALERT: Price-sensitive ASX Announcement for EPI
Current share price for EPI : $0.330 -0.065 (-16.46%)+
Announcement
Release
1 Jun 2026 8:33AM
Price at Release
$0.395
Full Release
download
Summary
Epiminder Limited announced reaching the milestone of enrolling the 25th patient in its DETECT study, which is a strategic part of its commercialisation plan for the innovative Minder® System. The study, conducted across 19 prestigious US clinical sites, aims to address significant gaps in epilepsy care by providing continuous EEG monitoring to support better clinical decision-making for patients with inconclusive traditional EEG results. The company targets enrolling 50 patients by mid Q3 CY2026 and ultimately plans to enroll 210 participants. This development marks a critical step in their strategy to expand access to advanced epilepsy therapies.
Key Points
  • Epiminder Limited reached the 25th patient enrolment in the DETECT study.
  • The DETECT study is a prospective, randomized, controlled US clinical study evaluating the Minder® System.
  • 19 leading clinical sites across the United States are participating in DETECT, including Mayo Clinic, Harvard, and Stanford.
  • The next enrolment target is 50 patients, expected by mid Q3 CY2026.
  • DETECT addresses a gap in epilepsy care caused by inconclusive inpatient EEG monitoring.
  • The study aims to enroll up to 210 participants across 25 US sites with a six-month primary follow-up.
  • The primary endpoint is the proportion of subjects achieving an actionable clinical event.
  • Minder® System provides continuous bilateral subscalp EEG monitoring.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.